Inclusion Criteria:

        •Patients must have Histologically or cytologically confirmed non small cell carcinoma of
        the lung who harbors EGFR-mutation and are previously disease progression to 3st generation
        EGFR-TKI Osimertinib.

        Patient must have measurable stage IV disease (includes M1a, M1b stages or recurrent
        disease) (according to the 7th edition of the tumor node metastasis (TNM) classification
        system). However, patients with T4NX disease (stage III B) with nodule(s) in ipsilateral
        lung lobe are not eligible, because such patients were not included in historical controls.

          -  Patients be age >18 years and < 75 years.

          -  Patients must have a Life Expectancy of greater than 12 weeks.

          -  Patients must have an electrocorticography (ECOG) performance status 0 or 1 (Karnofsky
             > 70).

          -  Patients must have normal organ and marrow function as defined below, within one week
             prior to randomization: absolute neutrophil count >1,500/mL platelets > 100,000/mL
             total bilirubin: within normal institutional limits AST(SGOT)/ALT(SGPT) < 2.5 X
             institutional upper limit of normal creatinine < 1.5 X institutional upper limit of
             normal urine dipstick for proteinuria of < less than 1+. If urine dipstick is > 1+
             then a 24 hour urine for protein must demonstrate < 500 mg of protein in 24 hours to
             allow participation in the study.

        Women of child-bearing potential and men must agree to use adequate contraception (hormonal
        or barrier method of birth control; abstinence) prior to study entry and for the duration
        of study participation. Should a woman become pregnant or suspect she is pregnant while
        participating in this study, she should inform her treating physician immediately.

          -  Patients must have an international normalized ratio (INR) < 1.5 and a partial
             thromboplastin time (PTT) no greater than upper limits of normal within 1 week prior
             to randomization.

          -  Patients with a history of hypertension must be well-controlled (<150 systolic/<100
             diastolic) on a stable regimen of anti-hypertensive therapy.

          -  Patients must have the ability to understand and the willingness to sign a written
             informed consent document.

        Exclusion Criteria:

          -  Patients with uncontrolled intercurrent illness including, but not limited to, ongoing
             or active infection,symptomatic congestive heart failure, unstable angina pectoris,
             cardiac arrhythmia,gastric ulcer,hemophilia,thrombopenia,active
             hemorrhage,podagra,kidney failure or psychiatric illness/social situation that would
             limit compliance with study requirements.

          -  Patients receiving chronic daily treatment with aspirin (> 325 mg/day) or nonsteroidal
             anti-inflammatory agents known to inhibit platelet function. Treatment with
             dipyridamole (Persantine), ticlopidine (Ticlid),clopidogrel (Plavix) and/or cilostazol
             (Pletal)is also not allowed.

          -  Patients receiving therapeutic anticoagulation. Prophylactic anticoagulation of venous
             access devices is allowed provided Section 3.10 is met. Caution should be taken on
             treating patients with low dose heparin or low molecular weight heparin for DVT
             prophylaxis during treatment with bevacizumab as there may be an increased risk of
             bleeding.

          -  Prior use of chemotherapy.

          -  Patients receiving immunotherapy, hormonal-therapy and or radiotherapy within 2 weeks
             prior to entering the study. Note: Those who have not recovered from adverse events
             due to these agents administered will be considered ineligible.

          -  Patients receiving any other investigational agents.

          -  Patients with uncontrolled brain metastasis. Note: Patients with brain metastases must
             have stable neurologic status following local therapy (surgery or radiation) for at
             least 2 weeks, and must be without neurologic dysfunction that would confound the
             evaluation of neurologic and other adverse events.

          -  Patients with a history of allergic reactions attributed to compounds of similar
             chemical or biologic composition to Osimertinib and Aspirin or other agents used in
             the study are excluded.

          -  Women that are pregnant or breastfeeding Note: Pregnant women are excluded from this
             study because the agents used in this study may be teratogenic to a fetus. Because
             there is an unknown but potential risk for adverse events in nursing infants secondary
             to treatment of the mother with paclitaxel, breastfeeding women are also excluded from
             this study.

          -  Patients that are HIV-positive on combination antiretroviral therapy due to the
             potential for lethal infections when treated with marrow-suppressive therapy.